173 related articles for article (PubMed ID: 21901385)
21. Effect of TRA-8 anti-death receptor 5 antibody in combination with chemotherapy in an ex vivo human ovarian cancer model.
Frederick PJ; Kendrick JE; Straughn JM; Della Manna DL; Oliver PG; Lin HY; Grizzle WE; Stockard CR; Alvarez RD; Zhou T; LoBuglio AF; Buchsbaum DJ
Int J Gynecol Cancer; 2009 Jul; 19(5):814-9. PubMed ID: 19574765
[TBL] [Abstract][Full Text] [Related]
22. Calmodulin antagonist enhances DR5-mediated apoptotic signaling in TRA-8 resistant triple negative breast cancer cells.
Fancy RM; Kim H; Napier T; Buchsbaum DJ; Zinn KR; Song Y
J Cell Biochem; 2018 Jul; 119(7):6216-6230. PubMed ID: 29663486
[TBL] [Abstract][Full Text] [Related]
23. Anti-tumor activity of an anti-DR5 monoclonal antibody, TRA-8, in combination with taxane/platinum-based chemotherapy in an ovarian cancer model.
Bevis KS; McNally LR; Sellers JC; Della Manna D; Londoño Joshi A; Amm H; Straughn JM; Buchsbaum DJ
Gynecol Oncol; 2011 Apr; 121(1):193-9. PubMed ID: 21211830
[TBL] [Abstract][Full Text] [Related]
24. Breast tumor xenografts: diffusion-weighted MR imaging to assess early therapy with novel apoptosis-inducing anti-DR5 antibody.
Kim H; Morgan DE; Zeng H; Grizzle WE; Warram JM; Stockard CR; Wang D; Zinn KR
Radiology; 2008 Sep; 248(3):844-51. PubMed ID: 18710978
[TBL] [Abstract][Full Text] [Related]
25. Synergistic interactions of chemotherapeutic drugs and tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand on apoptosis and on regression of breast carcinoma in vivo.
Singh TR; Shankar S; Chen X; Asim M; Srivastava RK
Cancer Res; 2003 Sep; 63(17):5390-400. PubMed ID: 14500373
[TBL] [Abstract][Full Text] [Related]
26. Noninvasive monitoring of pharmacodynamics and kinetics of a death receptor 5 antibody and its enhanced apoptosis induction in sequential application with doxorubicin.
Weber TG; Pöschinger T; Galbán S; Rehemtulla A; Scheuer W
Neoplasia; 2013 Aug; 15(8):863-74. PubMed ID: 23908588
[TBL] [Abstract][Full Text] [Related]
27. Cooperation of the agonistic DR5 antibody apomab with chemotherapy to inhibit orthotopic lung tumor growth and improve survival.
Jin H; Yang R; Ross J; Fong S; Carano R; Totpal K; Lawrence D; Zheng Z; Koeppen H; Stern H; Schwall R; Ashkenazi A
Clin Cancer Res; 2008 Dec; 14(23):7733-40. PubMed ID: 19047100
[TBL] [Abstract][Full Text] [Related]
28. Calmodulin Binding to Death Receptor 5-mediated Death-Inducing Signaling Complex in Breast Cancer Cells.
Fancy RM; Kim H; Zhou T; Zinn KR; Buchsbaum DJ; Song Y
J Cell Biochem; 2017 Aug; 118(8):2285-2294. PubMed ID: 28092099
[TBL] [Abstract][Full Text] [Related]
29. Enhancement of glioma radiotherapy and chemotherapy response with targeted antibody therapy against death receptor 5.
Fiveash JB; Gillespie GY; Oliver PG; Zhou T; Belenky ML; Buchsbaum DJ
Int J Radiat Oncol Biol Phys; 2008 Jun; 71(2):507-16. PubMed ID: 18474311
[TBL] [Abstract][Full Text] [Related]
30. Repeated treatment with subtoxic doses of TRAIL induces resistance to apoptosis through its death receptors in MDA-MB-231 breast cancer cells.
Yoshida T; Zhang Y; Rivera Rosado LA; Zhang B
Mol Cancer Res; 2009 Nov; 7(11):1835-44. PubMed ID: 19843632
[TBL] [Abstract][Full Text] [Related]
31. Multimeric Anti-DR5 IgM Agonist Antibody IGM-8444 Is a Potent Inducer of Cancer Cell Apoptosis and Synergizes with Chemotherapy and BCL-2 Inhibitor ABT-199.
Wang BT; Kothambawala T; Wang L; Matthew TJ; Calhoun SE; Saini AK; Kotturi MF; Hernandez G; Humke EW; Peterson MS; Sinclair AM; Keyt BA
Mol Cancer Ther; 2021 Dec; 20(12):2483-2494. PubMed ID: 34711645
[TBL] [Abstract][Full Text] [Related]
32. Enhanced metastasis suppression by targeting TRAIL receptor 2 in a murine model of triple-negative breast cancer.
Malin D; Chen F; Schiller C; Koblinski J; Cryns VL
Clin Cancer Res; 2011 Aug; 17(15):5005-15. PubMed ID: 21653692
[TBL] [Abstract][Full Text] [Related]
33. Targeted radiotherapy potentiates the cytotoxicity of a novel anti-human DR5 monoclonal antibody and the adenovirus encoding soluble TRAIL in prostate cancer.
Arafat W; Zhou T; Naoum GE; Buchsbaum DJ
J Egypt Natl Canc Inst; 2015 Dec; 27(4):205-15. PubMed ID: 26385392
[TBL] [Abstract][Full Text] [Related]
34. Cytotoxicity and radiosensitization effect of TRA-8 on radioresistant human larynx squamous carcinoma cells.
Wu F; Hu Y; Long J; Zhou YJ; Zhong YH; Liao ZK; Liu SQ; Zhou FX; Zhou YF; Xie CH
Oncol Rep; 2009 Feb; 21(2):461-5. PubMed ID: 19148523
[TBL] [Abstract][Full Text] [Related]
35. QLT0267, a small molecule inhibitor targeting integrin-linked kinase (ILK), and docetaxel can combine to produce synergistic interactions linked to enhanced cytotoxicity, reductions in P-AKT levels, altered F-actin architecture and improved treatment outcomes in an orthotopic breast cancer model.
Kalra J; Warburton C; Fang K; Edwards L; Daynard T; Waterhouse D; Dragowska W; Sutherland BW; Dedhar S; Gelmon K; Bally M
Breast Cancer Res; 2009; 11(3):R25. PubMed ID: 19409087
[TBL] [Abstract][Full Text] [Related]
36. Combination of cytosine deaminase suicide gene expression with DR5 antibody treatment increases cancer cell cytotoxicity.
Kaliberov SA; Chiz S; Kaliberova LN; Krendelchtchikova V; Della Manna D; Zhou T; Buchsbaum DJ
Cancer Gene Ther; 2006 Feb; 13(2):203-14. PubMed ID: 16082379
[TBL] [Abstract][Full Text] [Related]
37. Structural and functional analysis of the interaction between the agonistic monoclonal antibody Apomab and the proapoptotic receptor DR5.
Adams C; Totpal K; Lawrence D; Marsters S; Pitti R; Yee S; Ross S; Deforge L; Koeppen H; Sagolla M; Compaan D; Lowman H; Hymowitz S; Ashkenazi A
Cell Death Differ; 2008 Apr; 15(4):751-61. PubMed ID: 18219321
[TBL] [Abstract][Full Text] [Related]
38. Doxorubicin overcomes resistance to drozitumab by antagonizing Inhibitor of Apoptosis Proteins (IAPs).
Zinonos I; Labrinidis A; Liapis V; Hay S; Panagopoulos V; Denichilo M; Ponomarev V; Ingman W; Atkins GJ; Findlay DM; Zannettino AC; Evdokiou A
Anticancer Res; 2014 Dec; 34(12):7007-20. PubMed ID: 25503127
[TBL] [Abstract][Full Text] [Related]
39. A novel anti-DR5 chimeric antibody and epirubicin synergistically suppress tumor growth.
Qiu Y; Zhang Z; Shi J; Liu S; Liu Y; Zheng D
IUBMB Life; 2012 Sep; 64(9):757-65. PubMed ID: 22815059
[TBL] [Abstract][Full Text] [Related]
40. MEDI3039, a novel highly potent tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptor 2 agonist, causes regression of orthotopic tumors and inhibits outgrowth of metastatic triple-negative breast cancer.
Greer YE; Gilbert SF; Gril B; Narwal R; Peacock Brooks DL; Tice DA; Steeg PS; Lipkowitz S
Breast Cancer Res; 2019 Feb; 21(1):27. PubMed ID: 30777098
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]